Does Amerigroup Cover Eliquis?

What Is Eliquis and Why Do Patients Need It?

Eliquis is a brand-name oral anticoagulant containing apixaban, a direct Factor Xa inhibitor approved by the FDA for multiple cardiovascular indications. Patients prescribed apixaban typically have conditions carrying significant stroke or thromboembolism risk, making reliable insurance coverage a medical necessity rather than a preference.

FDA-Approved Indications for Apixaban

The FDA has approved apixaban for four distinct indications, each with its own dosing schedule [1]:

• Nonvalvular atrial fibrillation (AFib): 5 mg twice daily (or 2.5 mg twice daily if two or more of these apply: age 80+, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher) to reduce stroke and systemic embolism risk.
• DVT treatment: 10 mg twice daily for 7 days, then 5 mg twice daily.
• DVT/PE secondary prevention: 2.5 mg twice daily after at least 6 months of treatment.
• Post-surgical DVT prophylaxis: 2.5 mg twice daily after hip or knee replacement surgery.

The ARISTOTLE trial (N=18,201) showed apixaban reduced stroke or systemic embolism by 21% compared to warfarin in AFib patients, with a 31% reduction in major bleeding (P<0.001 for both) [2]. That evidence base is why physicians frequently prefer apixaban over older agents.

Why Coverage Matters Clinically

Without anticoagulation, a patient with AFib faces an annual stroke risk of 3-5% depending on CHA2DS2-VASc score [3]. Missing doses due to cost or coverage gaps directly increases that risk. The American Heart Association notes that cost-related nonadherence to anticoagulants is associated with a measurable increase in thromboembolic events [4].

How Amerigroup Formularies Work

Amerigroup, now operating under the Elevance Health (formerly Anthem) umbrella, administers Medicaid managed care and Medicare Advantage plans in more than a dozen states. Each state contract produces a separate formulary. That means Eliquis coverage in Georgia differs from coverage in Texas or Nevada.

Formulary Tiers Explained

Most Amerigroup plans use a four- or five-tier formulary structure:

| Tier | Category | Typical Member Cost | |------|----------|-------------------| | 1 | Preferred generics | $0 to $5 copay | | 2 | Non-preferred generics | $5 to $15 copay | | 3 | Preferred brands | $30 to $60 copay | | 4 | Non-preferred brands | $60 to $120 copay | | 5 | Specialty drugs | 20-33% coinsurance |

Eliquis sits on Tier 3 or Tier 4 in most Amerigroup commercial and Medicare Advantage formularies. For Medicaid beneficiaries, copays are capped by federal regulations at nominal amounts (typically $4 or less per prescription), but prior authorization requirements still apply regardless of cost share.

Generic Apixaban and the Formulary Shift

The FDA approved the first generic apixaban in May 2023 following resolution of patent litigation [5]. Generic entry typically causes plans to shift the brand to a higher tier while placing the generic at Tier 1 or Tier 2. If your Amerigroup plan now lists a generic apixaban at Tier 1, your out-of-pocket cost may be $0 to $10 per fill even without prior authorization. Call the member services number on your insurance card to confirm your plan's current generic tier placement.

Prior Authorization Requirements for Eliquis on Amerigroup

Prior authorization (PA) is the most common barrier to Eliquis access on Amerigroup plans. The plan requires your prescriber to submit clinical documentation proving the drug is medically necessary for your specific diagnosis.

What Amerigroup Typically Requires for PA Approval

Documentation requirements vary by state contract, but the following criteria appear consistently across Amerigroup PA policies for apixaban:

1. A confirmed FDA-approved diagnosis (AFib documented by EKG or Holter, confirmed DVT/PE by imaging, or scheduled joint replacement surgery).
2. Prescriber attestation that the patient has a contraindication, documented intolerance, or therapeutic failure with a preferred anticoagulant (usually warfarin or, in some plans, rivaroxaban).
3. INR monitoring history if warfarin was trialed, showing either poor time-in-therapeutic-range (TTR) or documented bleeding.
4. Current lab values: serum creatinine, hepatic function tests, and complete blood count within the past 90 days.

The 2023 American College of Cardiology/American Heart Association AFib guideline states: "For patients with AF and CHA2DS2-VASc score of 2 or greater in men or 3 or greater in women, anticoagulation with a non-vitamin K oral anticoagulant (NOAC) is recommended over warfarin" (Class I, Level A evidence) [6]. That guideline language is the single most effective clinical justification your physician can include in a PA request.

Step Therapy: Warfarin First Policies

Some Amerigroup state plans require a warfarin trial before approving apixaban. If your physician can document any of the following, step therapy can usually be bypassed [7]:

• Labile INRs (TTR <65% despite adherence)
• History of warfarin-induced skin necrosis
• Dietary restrictions incompatible with stable INR management
• Patient occupation or lifestyle making frequent INR monitoring impractical
• Genetic CYP2C9 or VKORC1 variants predicting warfarin instability

The HealthRX Prior Authorization Readiness Framework for Apixaban outlines the five documentation categories a prescriber should assemble before submitting a PA request to any Amerigroup plan: (1) diagnostic confirmation, (2) preferred-agent contraindication or failure, (3) guideline citation matching the patient's CHA2DS2-VASc or Padua score, (4) current renal and hepatic labs, and (5) a one-paragraph clinical narrative tying all elements to medical necessity. Plans that receive all five categories in the initial submission approve at measurably higher rates than those receiving incomplete packets.

PA Turnaround Times

Federal Medicaid regulations and CMS standards require standard PA decisions within 3 business days and urgent (expedited) PA decisions within 24 hours when a prescriber certifies that the standard timeframe could jeopardize the patient's health [8]. If Amerigroup exceeds those windows, your prescriber can file an expedited review request citing those federal timelines.

What to Do When Amerigroup Denies Eliquis Coverage

A denial is not a final answer. Federal and state law guarantee you the right to appeal, and roughly 40-60% of initial PA denials are overturned at the first level of appeal when complete documentation is submitted.

The Four-Level Appeals Process

Level 1: Internal Plan Appeal. Submit a written appeal within the timeframe stated on your denial letter (typically 30 to 60 days). Your physician should include the ACC/AHA guideline reference cited above, the clinical narrative, and any additional lab results. Standard internal appeals must be decided within 30 days; expedited within 72 hours.

Level 2: External Independent Review. If the internal appeal fails, you have the right to an external review by an independent organization not affiliated with Amerigroup. All states participating in ACA-regulated plans must offer this pathway.

Level 3: State Medicaid Fair Hearing. For Medicaid members specifically, you can request a state Medicaid fair hearing through your state's Medicaid agency. Federal law requires the hearing be scheduled within 90 days of request, and your benefits may continue at the same level during the hearing process.

Level 4: State Insurance Commissioner Complaint. Filing a complaint with your state's insurance commissioner places regulatory pressure on the plan and creates a documented record that may support further legal action if necessary.

Urgent Bridge Therapy

While an appeal is pending, ask your physician whether a 30-day bridge prescription of generic warfarin is clinically appropriate. Warfarin is universally covered at $0 copay on virtually all Medicaid plans and can maintain anticoagulation while the appeal resolves. This is not ideal for every patient (particularly those with a documented warfarin contraindication), but it prevents dangerous gaps in coverage.

Cost and Patient Assistance Options If Coverage Fails

Even without Amerigroup approval, several programs may reduce or eliminate your out-of-pocket cost for Eliquis.

Bristol-Myers Squibb / Pfizer Patient Assistance

Bristol-Myers Squibb and Pfizer co-market Eliquis and offer two assistance programs:

• Eliquis $10 Copay Card: Available to commercially insured patients (not Medicaid or Medicare). Reduces cost share to as low as $10 per 30-day fill. Eligible patients can enroll at the manufacturer's enrollment portal.
• BMS Patient Assistance Foundation: For uninsured or underinsured patients with household income below approximately 200-400% of the federal poverty level. Provides Eliquis at no cost. Applications require prescriber participation and income verification.

Medicaid beneficiaries are federally excluded from using manufacturer copay cards, but they remain eligible for the Patient Assistance Foundation if they lose Medicaid coverage or have a coverage gap.

GoodRx and Pharmacy Discount Programs

Generic apixaban prices through GoodRx or similar discount programs have fallen sharply since the 2023 generic launch. At major pharmacy chains, a 60-tablet supply of generic apixaban 5 mg (one month of twice-daily dosing) may be available for $30 to $80 depending on location and pharmacy. This is significantly lower than the $500+ cash price for brand-name Eliquis [9].

State Pharmaceutical Assistance Programs (SPAPs)

Fifteen states operate SPAPs that provide additional drug cost assistance to Medicare beneficiaries who hit coverage gaps. If you have both Amerigroup Medicare Advantage and your state offers an SPAP, you may qualify for supplemental coverage. The Medicare Interactive resource maintained by the Medicare Rights Center lists current SPAP availability by state.

Verifying Your Specific Amerigroup Plan's Current Formulary

Formularies change annually and sometimes mid-year. The most reliable way to confirm current Eliquis or generic apixaban coverage on your specific Amerigroup plan is:

Three Reliable Verification Methods

1. Online formulary search tool. Log into your Amerigroup member portal and use the drug lookup tool. Enter "apixaban" (generic) and "Eliquis" (brand) separately, as they may appear on different tiers.

2. Pharmacy benefits call. Call the pharmacy benefits number on the back of your Amerigroup insurance card (separate from the medical benefits number). Ask specifically: "Is apixaban on the formulary? What tier? Is prior authorization required? Is step therapy required?"

3. Prescriber office verification. Many cardiology and internal medicine offices have staff who perform benefits verification before prescribing a new anticoagulant. Ask the office to run a real-time eligibility and formulary check through their electronic prescribing system.

The CMS requires all Medicare Part D plans (including Medicare Advantage with prescription drug coverage) to publish their formularies publicly and to notify members of any formulary changes at least 60 days before the change takes effect [8]. Medicaid managed care organizations operate under similar state contract requirements.

Clinical Context: Who Prescribes Apixaban and Why?

Understanding why apixaban is prescribed helps frame the PA conversation with Amerigroup's medical reviewers.

Apixaban Versus Warfarin: The Evidence

The ARISTOTLE trial established apixaban's superiority over warfarin in AFib patients across all three primary endpoints: stroke/systemic embolism, major bleeding, and all-cause mortality [2]. The absolute risk reduction for major bleeding was 1.18% per year, translating to a number needed to treat of 84 patients per year to prevent one major bleed. That is not a trivial safety advantage.

For VTE treatment, the AMPLIFY trial (N=5,395) showed apixaban reduced major bleeding by 69% compared to conventional therapy (enoxaparin followed by warfarin), with equivalent VTE recurrence rates [10]. The FDA approved apixaban for VTE treatment based largely on that trial.

Renal Dosing Considerations

Patients with chronic kidney disease present a specific prescribing challenge. The FDA label specifies dose reduction to 2.5 mg twice daily in AFib patients meeting two of three criteria: age 80 or older, weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [1]. Apixaban is generally preferred over other NOACs in moderate CKD (eGFR 25-50 mL/min/1.73m2) because renal clearance accounts for only about 27% of total drug elimination, compared to 80% for dabigatran and 33% for rivaroxaban [11]. Including this pharmacokinetic rationale in a PA request for a CKD patient may strengthen the case for apixaban specifically over a covered alternative.

State-by-State Coverage Variability

Amerigroup operates Medicaid managed care contracts in Georgia, Indiana, Kansas, Louisiana, Maryland, Nevada, New Jersey, New Mexico, New York, Tennessee, Texas, Virginia, and Washington. Each state's Medicaid agency negotiates its own preferred drug list (PDL) and PA criteria separately.

States with more restrictive PDLs may require warfarin trial documentation spanning 90 days with documented TTR records before considering NOAC PA approval. States with less restrictive PDLs may approve apixaban PA on the basis of an AFib diagnosis and CHA2DS2-VASc score alone without requiring a warfarin trial. Your prescriber's office should contact Amerigroup in your specific state to obtain the current PA criteria document before submitting.

The Medicaid and CHIP Payment and Access Commission (MACPAC) has noted in its congressional reports that NOAC access under Medicaid managed care varies substantially by state and plan, creating equity concerns for anticoagulant-dependent patients [12].